Log in or register to see all Alerts
New HTA Decisions in Scotland
March 2021
Drug name
DUPIXENT® (dupilumab)
Sanofi Genzyme
Decision date
Therapeutic area
Ear, nose and throat conditions
Therapeutic sub area
Nasal conditions
Not recommended
As an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
Decision Detail
In the absence of a submission from the holder of the marketing authorisation, dupilumab (DUPIXENT®) is not recommended for use within NHS Scotland.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result they cannot recommend its use within NHS Scotland.